PMID- 37625520
OWN - NLM
STAT- MEDLINE
DCOM- 20231002
LR  - 20231011
IS  - 1879-016X (Electronic)
IS  - 0163-7258 (Linking)
VI  - 250
DP  - 2023 Oct
TI  - Repurposing of antiangiogenic agents for treatment of vascular anomalies.
PG  - 108520
LID - S0163-7258(23)00184-5 [pii]
LID - 10.1016/j.pharmthera.2023.108520 [doi]
AB  - Vascular anomalies (VA) are developmental anomalies of veins, arteries, 
      lymphatics or capillaries thought to be caused by mutations in genes that drive 
      angiogenesis. Treatments targeting these genes are limited. We review the 
      literature for conventional medications and products from traditional medicine 
      cultures that have been found to have antiangiogenic activity. Fewer than 50 
      drugs with credible human activity in VA were identified and include beta blockers, 
      monoclonal antibodies, microtubule inhibitors, multi-kinase inhibitors, PIK3CA- 
      and RAS-MAPK pathway inhibitors, and thalidomides. Other drug categories of 
      potential interest are ACE-inhibitors, antifungals, antimalarials, 
      MMP9-inhibitors, and over-the-counter compounds used in Eastern traditional 
      medicine. Low toxicity for some offers the possibility of combined use with known 
      effective agents. In addition to already familiar drugs, others with 
      antiangiogenic capabilities already in use in children or adults may deserve 
      further attention for repurposing for VA.
CI  - Copyright (c) 2023 Elsevier Inc. All rights reserved.
FAU - Blatt, Julie
AU  - Blatt J
AD  - Division of Hematology Oncology, Department of Pediatrics, and the Lineberger 
      Clinical Cancer Center, University of North Carolina School of Medicine, Chapel 
      Hill, NC, USA. Electronic address: jblat@med.unc.edu.
FAU - Brondon, Jennifer E
AU  - Brondon JE
AD  - Division of Hematology Oncology, Department of Pediatrics, and the Lineberger 
      Clinical Cancer Center, University of North Carolina School of Medicine, Chapel 
      Hill, NC, USA.
FAU - Nieman, Elizabeth L
AU  - Nieman EL
AD  - Department of Dermatology, Univerity of North Carolina School of Medicine, Chapel 
      Hill, NC, USA.
FAU - Phillips, Kynlon
AU  - Phillips K
AD  - The Department of Pharmacy, University of North Carolina Hospitals, Chapel Hill, 
      NC, USA.
FAU - Pandya, Arti
AU  - Pandya A
AD  - Division of Genetics and Metabolism, Department of Pediatrics, University of 
      North Carolina School of Medicine, Chapel Hill, NC, USA.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20230823
PL  - England
TA  - Pharmacol Ther
JT  - Pharmacology & therapeutics
JID - 7905840
RN  - 0 (Angiogenesis Inhibitors)
RN  - 0 (Antibodies, Monoclonal)
SB  - IM
MH  - Child
MH  - Humans
MH  - *Angiogenesis Inhibitors/pharmacology/therapeutic use
MH  - *Drug Repositioning
MH  - Antibodies, Monoclonal/therapeutic use
OTO - NOTNLM
OT  - Antiangiogenesis
OT  - Drug repurposing
OT  - Vascular anomaly
OT  - Vascular malformation
COIS- Declaration of Competing Interest Drs. Blatt and Brondon are site investigators 
      for Novartis. Dr. Blatt has been a speaker for Novartis-underwritten sessions by 
      Axis and Medscape. All authors declare that they have no other conflicts of 
      interest.
EDAT- 2023/08/26 05:41
MHDA- 2023/10/02 06:42
CRDT- 2023/08/25 19:25
PHST- 2023/05/02 00:00 [received]
PHST- 2023/07/15 00:00 [revised]
PHST- 2023/08/21 00:00 [accepted]
PHST- 2023/10/02 06:42 [medline]
PHST- 2023/08/26 05:41 [pubmed]
PHST- 2023/08/25 19:25 [entrez]
AID - S0163-7258(23)00184-5 [pii]
AID - 10.1016/j.pharmthera.2023.108520 [doi]
PST - ppublish
SO  - Pharmacol Ther. 2023 Oct;250:108520. doi: 10.1016/j.pharmthera.2023.108520. Epub 
      2023 Aug 23.